Vascular cognitive impairment is the second most common cause of dementia after Alzheimer's disease and is expected to grow in prevalence with the aging global population. The purpose of this authoritative book is to give a broad clinical perspective on vascular cognitive impairment and thus create a foundation for the implementation of good dementia care. The book focuses on pathophysiology, diagnosis, treatment and prevention. It demonstrates the underlying causes of the disorder, such as the manner in which vascular risk-factors influence the onset of vascular cognitive impairment. The concept of mixed forms of vascular dementia, Alzheimer's dementia and other vascular diseases is discussed as well as the influence of vascular changes with regard to the onset of Alzheimer's disease. The detailed section on pathophysiology will enhance clinicians' understanding of this complex disorder. Finally there is a section on pharmacological and neuropsychological treatment of cognitive and psychiatric symptoms.Galantamine is a cholinesterase inhibitor that also modulates central nicotinic receptors to increase cholinergic ... combined with CVD, who received galantamine 24 mg per day (n:396) or placebo (n: 196) over 6months (Erkinjuntti et al., 2002). ... In an open-label extension, the original galantamine group with probable VaD or AD with CVD showed similar sustained benefits in terms of maintenance of oranbsp;...
|Title||:||Vascular Cognitive Impairment in Clinical Practice|
|Author||:||Lars-Olof Wahlund, Timo Erkinjuntti, Serge Gauthier|
|Publisher||:||Cambridge University Press - 2009-02-12|